Biotech Values

[dewophile]

perhaps a collaboration is in the offing?
i say that tongue in cheek - i doubt it is a serious pursuit given the lack of perceived advantage of recombinant agents based on recothrom adoption. then again bruce carter stated in no uncertain terms COGs for recothrom was better than evicel - so in theory if they can make a recombinant sealant and compete on price there could be potential there
i'm not so sure it's as easy as just mixing thrombin and fibrinogen though..